Preoperative chemotherapy for operable breast cancer is associated with better compliance with adjuvant therapy in matched stage II and IIIA patients

Oncologist

Volumn 16, Issue 6, 2011, Pages 742-751

  Komenaka, Ian K ^a,b   Hsu, Chiu Hsieh ^b,c   Martinez, Maria Elena ^b,c   Bouton, Marcia E ^a   Low, Boo Ghee ^d   Salganick, Jason A ^e   Nodora, Jesse ^b,c   Hibbard, Michael L ^a   Jha, Chandra ^a  

^a MARICOPA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Southwest Hematology Oncology   (United States)

^e Arizona Oncology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; HORMONE; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PREOPERATIVE CHEMOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LOGISTIC MODELS; MATCHED-PAIR ANALYSIS; MIDDLE AGED; NEOPLASM STAGING; PATIENT COMPLIANCE; PREOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SMOKING;

EID: 79959581565     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0266     Document Type: Article

References (31)

1. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
2. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cy-clophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. JClin Oncol 2003;21:4165-4174.
3. Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
4. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; (30):96-102.
5. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophospha-mide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-2027.
6. Boughey JC, Peintinger F, Meric-Bernstam F et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 2006;244:464-470.
7. National Surgical Adjuvant Breast and Bowel Project. Information on Protocol B-40. Available at http://www.nsabp.pitt.edu/B40_Information.asp, accessed August 1, 2010.
8. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, pac-litaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
9. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive valueof the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
10. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
11. Lin Y, Lin S, Watson M et al. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2010;123:691-699.
12. Boughey JC, Wagner J, Garrett BJ et al. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol 2009;16:1606-1611.
13. Carlson RW, Allred DC, Anderson BO et al. Breast cancer. Available at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf, accessed August 1, 2010.
14. Hokanson P, Seshadri R, Miller KD. Underutilization of breast-conserving therapy in a predominantly rural population: Need for improved surgeon and public education. Clin Breast Cancer 2000;1:72-76.
15. Punglia RS, Weeks JC, Neville BA et al. Effect of distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women. Int J Radiat Oncol Biol Phys 2006;66:56-63.
16. Voti L, Richardson LC, Reis IM et al. Treatment of local breast carcinoma in Florida: The role of the distance to radiation therapy facilities. Cancer 2006;106:201-207.
17. Balasubramanian SP, Murrow S, Holt S et al. Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network. Breast 2003;12:136-141.
18. Landercasper J, Dietrich LL, Johnson JM. A breast center review of compliance with National Comprehensive Cancer Network breast cancer guidelines. Am J Surg 2006;192:525-527.
19. Komenaka IK, Pennington RE Jr, Schneider BP et al. Compliance differences between patients with breast cancer in university and county hospitals. Clin Breast Cancer 2010;10:385-391.
20. Ma AM, Barone J, Wallis AE et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 2008;196:500-504.
21. Bickell NA, Le Par F,Wang JJ et al. Lost opportunities: Physicians' reasons and disparities in breast cancer treatment. J Clin Oncol 2007;25:2516-2521.
22. de Azambuja E, McCaskill-Stevens W, Francis P et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial. Breast Cancer Res Treat 2010;119:145-153.
23. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005;165:1267-1273.
24. Haslam DW, James WP. Obesity. Lancet 2005;366:1197-1209.
25. Peeters A, Barendregt JJ, Willekens F et al.; NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: A life-table analysis. Ann Intern Med 2003;138:24-32.
26. Shah ND, Dunlay SM, Ting HH et al. Long-term medication adherence after myocardial infarction: Experience of a community. Am J Med 2009; 122:961.e7-e13.
27. Berecki-Gisolf J, Hockey R, Dobson A. Adherence to bisphosphonate treatment by elderly women. Menopause 2008;15:984-990.
28. Webb MS, Vanable PA, Carey MP et al. Medication adherence in HIV-infected smokers: The mediating role of depressive symptoms. AIDS Educ Prev 2009;21(3 suppl):94-105.
29. Buchholz TA, Theriault RL, Niland JC et al. The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers. J Clin Oncol 2006;24:361-369.
30. Komenaka IK, Martinez ME, Pennington RE Jr et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst 2010;102:1178-1187.
31. Partridge AH, Wang PS, Winer EP et al. Nonadherence to adjuvant tamox-ifen therapy in women with primary breast cancer. J Clin Oncol 2003;21: 602-606.